REVIEW

α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease

Zachary A. Sorrentino[1] · Benoit I. Giasson[1] · Paramita Chakrabarty[1]

Abstract

α-Synuclein is a soluble protein that is present in abundance in the brain, though its normal function in the healthy brain is poorly defined. Intraneuronal inclusions of α-synuclein, commonly referred to as Lewy pathology, are pathological hallmarks of a spectrum of neurodegenerative disorders referred to as α-synucleinopathies. Though α-synuclein is expressed predominantly in neurons, α-synuclein aggregates in astrocytes are a common feature in these neurodegenerative diseases. How and why α-synuclein ends up in the astrocytes and the consequences of this dysfunctional proteostasis in immune cells is a major area of research that can have far-reaching implications for future immunobiotherapies in α-synucleinopathies. Accumulation of aggregated α-synuclein can disrupt astrocyte function in general and, more importantly, can contribute to neurodegeneration in α-synucleinopathies through various pathways. Here, we summarize our current knowledge on how astrocytic α-synucleinopathy affects CNS function in health and disease and propose a model of neuroglial connectome altered by α-synuclein proteostasis that might be amenable to immune-based therapies.

Abbreviations

αSyn	α-Synuclein
AKT	'AK' thymoma
ARE	Anti-oxidant response element
CNS	Central nervous system
CDNF	Cerebral dopamine neurotrophic factor
CSF	Cerebrospinal fluid
DAMP	Damage associated molecular pattern
DLB	Dementia with Lewy bodies
DNTC	Diffuse neurofibrillary tangles with calcification
EM	Electron microscope
FA	Formic acid
Foxa1	Forkhead box A1
GABA	Gamma-amino butyric acid
GDNF	Glial cell line-derived neurotrophic factor
GCI	Glial cytoplasmic inclusions
GFAP	Glial fibrillary acidic protein
GLP1R	Glucagon-like peptide-1 receptor
GBA	Glucocerebrosidase
H&E	Hematoxylin and eosin staining
HLA-DR	Human leukocyte antigen-DR isotype
LBVAD	Lewy body variant Alzheimer's disease
MHC-II	Major histocompatibility complex class II
MMP	Matrix metalloproteinase
MANF	Mesencephalic astrocyte-derived neurotrophic factor
iLBD	Incidental Lewy body diseases
Keap1	Kelch-like ECH-associated protein 1
LRRK2	Leucine-rich repeat kinase 2
LB	Lewy bodies
LN	Lewy neurites
MSA	Multiple system atrophy
NQO1	NAD(P)H quinone dehydrogenase 1
NCI	Neuronal cytoplasmic inclusions
NRTN	Neurturin
NAC	Non-amyloid β component
Nrf2	Nuclear factor erythroid 2-like 2
NFκB	Nuclear factor κ-light-chain-enhancer of activated B cells

✉ Paramita Chakrabarty
pchakrabarty@ufl.edu

1 Department of Neuroscience, Center for Translational Research in Neurodegenerative Diseases and McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA

Nurr1/NR4A2	Nuclear receptor subfamily 4, group A, member 2
PD	Parkinson's disease
PARK	Parkinson's disease-associated gene
PDD	PD with dementia
PI3K	Phosphatidylinositol 3-kinase
PDGFβ	Platelet-derived growth factor β
PET	Positron-emission tomography
pSer129	Phosphorylated serine 129
PINK1	Pten-induced putative kinase 1
ROS	Reactive oxygen species
SLA	Star like astrocyte
SNpc	Substantia Nigra pars compacta
SQSTM1	Sequestosome 1
Thy-1	Thymocyte differentiation antigen 1
TLR	Toll-like receptor
TNT	Tunneling nanotube

Introduction

Intraneuronal inclusions of α-synuclein (αSyn) protein, commonly referred to as Lewy bodies (LB) or Lewy neurites (LN), are hallmark pathologies in a group of neurodegenerative disorders collectively known as α-synucleinopathies [13, 164]. The gene coding for the αSyn protein, *SNCA*, is a genetic risk factor for both sporadic and familial forms of multiple α-synucleinopathies, including Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB) [70, 139]. αSyn aggregates are found in different cell types as well as in different brain regions across the spectrum of α-synucleinopathies. For example, intraneuronal LB and LN pathology are frequently observed in PD, PD with dementia (PDD), incidental Lewy body disease (iLBD) and DLB (Fig. 1 d, h). In multiple system atrophy (MSA) patients, in addition to few neuronal cytoplasmic inclusions (NCI) of αSyn, αSyn inclusions are primarily found in oligodendrocytes and are referred to as glial cytoplasmic inclusions (GCIs) or Papp–Lantos bodies [75] (Fig. 1e, g). On the other hand, astrocytic inclusions of αSyn are invariant features in PD and DLB but observed less frequently in MSA (Fig. 1a–c) [145]. The clinical and neuropathological heterogeneity in the spectrum of α-synucleinopathies is believed to result from a combination of various factors, including unique conformational variants of αSyn protein that might contribute to distinct clinical phenotypes [118, 121].

αSyn was originally identified from an immunosera raised against purified cholinergic vesicles of the Torpedo electric organ and was also detected in the nucleus [101], resulting in the portmanteau designation of 'synuclein' (protein present in the synapse and nucleus). αSyn has been shown to exist as an inherently disordered monomer [161] or more controversially, as tetramers [15]. The N terminus of αSyn forms an amphipathic α helix structure, whereas the highly acidic C terminus, which exists as a random coil, stabilizes the structure by transiently interacting with the N terminus [18, 55]. The non-amyloid β component (NAC) domain found in the middle of the protein is hydrophobic and is required for αSyn to polymerize into amyloid fibrils [89]. The N terminus has a unique repeated motif of seven 11-amino acid residues and all the known PD-associated mutations (A30P, E46K, H50Q, A53E, A53T, G51D) tend to cluster in this domain. This motif is key to interaction between αSyn and membranes. The physiological function of αSyn remains highly debated, though several studies have shown that it plays a highly diverse role in the CNS–synaptic vesicle trafficking [116], lipid metabolism and membrane remodeling [115, 172], synaptic plasticity [59], molecular chaperoning [129] and mitochondrial membrane remodeling [111]. The natively unfolded structure of αSyn is determined by its low hydrophobicity and high net charge (pI of 4.7 at neutral pH). Destabilization of the native structure, possibly through post-translational modification or interactions with proteins or cell membranes, induces formation of insoluble oligomers or fibrils with highly ordered β-sheet conformation [62]. Phosphorylation at Serine 129 and C-terminal truncation products have both been shown to be common species in insoluble LB, LN and GCIs [5] and though controversial, some studies have shown that phosphorylation at Ser129 and C-terminal truncation can modulate αSyn fibrillization [54, 147].

Clinical research suggests that the predilection for astrocytic αSyn buildup in the temporal lobe of DLB and advanced PD patients may play a role in the symptomatic progression of these diseases and warrants further study to understand associated functional impairments [22]. It is generally believed that specific clinico-pathologic outcomes, representative of the heterogeneity observed in α-synucleinopathies, may be traced to the involvement of neuronal as well as glial αSyn pathology [119, 121, 122]. The biological mechanisms that trigger the normally soluble protein αSyn to aggregate into pathological inclusions, such as GCI, LB and LN, remains highly debated. Factors relating to the cellular environment, such as autophagic impairment, mitochondrial dysfunction, vesicular trafficking, oxidative stress, ER stress and inflammatory stress as well as factors related to αSyn metabolism, such as post translational modifications (nitrosylation or proteolytic processing) may promote αSyn aggregation in neurons [26, 60, 82, 94, 109, 137, 147]. On the other hand, the provenance of astrocyte-resident αSyn remains unclear as αSyn is expressed predominantly from neurons in both human and mice. It is thought that astrocytes accumulate αSyn by scavenging extracellular αSyn released from the neurons through an active process or following the demise of neurons containing these pathological αSyn inclusions [93, 97,

Fig. 1 Astrocytic αSyn inclusions in DLB patients specifically detected by an antibody in the middle domain of αSyn. **a** Immunohistochemical staining with 3H11 antibody raised against residues 43-63 of αSyn with formic acid retrieval. αSyn is extensively detected within astrocytes in the hippocampus of a DLB patient. **b** Higher magnification from **a** showing astrocytes immunopositive for αSyn antibody 3H11. **c** Immunofluorescent analysis with antibodies to GFAP (green) and αSyn 3H11 (red) demonstrating that αSyn is present in astrocytic processes in the DLB hippocampus. **d** Detection of αSyn within classical LBs in the substantia nigra of a DLB patient with the 3H11 antibody. Inset shows magnified view of a typical intraneuronal LB. **e** Detection of αSyn within GCI inclusions in the cerebellum of an MSA individual using the 3H11 antibody. Inset shows magnified view of typical GCI. **f** αSyn antibody 3H11 fails to show any immunoreactivity in the hippocampus of an Alzheimer's disease patient negative for pSer129 αSyn inclusions. **g** Immunohistochemical staining of the MSA cerebellum from **e** using antibody EP1536Y against pSer129 αSyn. **h** Immunohistochemical staining of the DLB hippocampus from **a** using antibody EP1536Y against pSer129 αSyn showing extensive NCI. **i** A western blot of 200 ng recombinant αSyn proteins harboring various familial mutations probed with antibody 94-3A10 (residues 130–140) [45]. **j** A western blot using the same proteins from **g** but probed with antibody 3H11; the antigenic region is residues ~47–55. **k** Western blot showing that 3H11 specifically recognizes human αSyn but not βSyn or γSyn. Scale bar: 100 μm (**a**, **d**–**h**), 50 μm (**c**)

130]. In some cases, astrocytes containing αSyn inclusions are found distal to extracellular LBs or dead neurons and sometimes even outnumber LB positive neurons, which may also suggest a de novo mechanism [22]. Observations in experimental animal models have also suggested that distinct αSyn conformers formed in the neurons are capable of templating normal soluble αSyn through a prion-like process [165]. Following a prion-like seeding process, pathological αSyn conformers can potentially be passaged through inter-neuronal or even neuro-astroglial connections and result in astrocytic accumulation of pathologic αSyn [1, 98]. However, overall very little mechanistic details are known regarding the role of these ubiquitous cells in the pathogenesis of α-synucleinopathies. To understand whether astrocytes play a beneficial or detrimental role, we examined the literature on interaction between pathologic αSyn and astrocytes in the context of cellular models, in vivo experimentation, and human disease. In the next sections, we will discuss how αSyn broadly affects the immune system and proceed to understanding the specific ways that αSyn accumulation alters astrocyte function and CNS homeostasis.

αSyn activates the immune system

Innate immune activation is a cardinal neuropathological feature accompanying end-stage α-synucleinopathy in patients and preclinical models (reviewed in Refs. [4, 27]). Curiously, the association of viral infection with Parkinsonism symptoms in von Economo's and postencephalitic PD patients spurred the idea that peripheral immune activation can trigger PD type neurodegeneration [128]. One of the earliest neuropathological demonstrations of CNS immune activation in PD patients showed increased HLA-DR (human leukocyte antigen DR isotype) positive reactive microglia [102, 162], though PD patients often do not show typical hypertrophic reactive astrocytes [145]. Interestingly, as discussed in more details in later sections, while subcortical protoplasmic astrocytes accumulate αSyn in PD, MSA patients do not typically show αSyn immunoreactive astrocytes [145]. Later studies showed that PD patients show elevated CSF levels of inflammatory cytokines such as IL-1β and IL-6 [19]. More recent studies have used cutting edge imaging and immunophenotyping studies to explore the link between inflammation and α-synucleinopathies. DLB patients with mild impairment displayed increased gliosis (using [(11)C]PK11195 PET tracer) in specific areas of the brain such as the caudate nucleus and cuneus compared to patients with more severe impairment, suggesting that inflammatory changes may occur in the early stages of disease [153]. Concomitant with CNS changes, these patients showed elevated peripheral blood inflammatory cytokines, such

as MIP-3, IL-17A and IL-2 [153]. This is consistent with a recent seminal demonstration that PD patients have a unique T cell signature [151]. This study identified IL5-producing CD4 + T cells and IFN-γ producing CD8 + cytotoxic T cells in PD patients that were reactive to native as well as protofibrillar forms of αSyn. Several genome-wide association studies have unearthed a link between HLA locus (human leukocyte antigen locus encoding the major histocompatibility complex class II (MHC-II)) and PD, strongly linking immune response as a risk factor in α-synucleinopathies [34]. Together these results show a functional link between activation of innate and adaptive immunity and α-synucleinopathies.

As a typical damage-associated molecular pattern (DAMP) containing moiety, αSyn aggregates or conformers has been shown to directly interact with astrocytes and microglia via pattern recognition receptors, including Toll-like receptor (TLR) 4 in cell culture [35, 93, 127, 179]. While αSyn aggregates have been specifically identified in hypertrophic 'activated' astrocytes in patient brains, whether the astrocytic inclusions themselves directly compromise these cells and trigger further cell- and non-cell autonomous damage and intercellular αSyn transmission is hotly debated. αSyn-induced chronic astrocyte activation can also lead to bystander pathologies, such as increased cytokine and chemokine expression, antigen presentation, Ca^{2+} flux and oxidative stress that can ultimately lead to maladaptive neuronal activity and neurodegeneration by non-cell autonomous mechanisms [6, 35, 93].

Based on neuropathological findings in limited cohorts of PD patients [14, 24, 63, 170] and the abundance of non-motor prodromal symptoms in PD patients [12], the gut–brain axis in PD was proposed which hypothesizes that initial αSyn aggregation can occur in the myenteric plexus of the gut (and other mucosal surfaces) which then propagates along vagal projections to the brain in a prion-like manner. There is indirect evidence of the involvement of peripheral immunity and the gut microbiome composition in induction and propagation of PD pathologies (reviewed in [80]). Indeed, the composition of PD patient gut microbiome is different from age-matched controls [77, 138] and transplantation of PD patient gut microbiota in a mouse model enhances motor deficits [135]. This latter study also showed for the first time that altering the gut microbiome composition modifies αSyn pathophysiology in the CNS of mice [135]. Since αSyn is expressed in enteric neurons [16] and can be physiologically secreted via a conventional, endoplasmic reticulum/Golgi-dependent exocytosis in a neuronal activity-regulated manner [117], it is easy to envisage that αSyn present in the gut can promote gut inflammation and contribute to αSyn pathogenesis along the gut–brain axis. However, it remains to be seen whether astrocytes (or other immune cells) in the enteric plexus play additional

role in gut inflammation or the induction and spread of αSyn pathologies along the gut–brain axis.

Recent advances in single-cell transcriptomics and mathematical modeling have revealed regional, functional and disease state-specific heterogeneity in brain resident astrocytes [78], suggesting that astrocyte diversity in different brain regions may also affect neural circuits differentially depending on the spatio-temporal context of the underlying αSyn pathology. Interestingly, identification of MHCI in a subset of neurons also infers that the neurons may not be immune privileged after all and may dynamically interact with alterations in glial cell function [42]. Thus it is possible that a specific combination of the cellular context [121], immune milieu [176] and/or αSyn conformers [118] will determine region-specific immune response including astrocyte function [154]. This complex interrelationship between innate immunity, peripheral immunity and dysfunctional CNS proteostasis can likely alter disease progression and the phenotypic manifestation in different α-synucleinopathies. A mechanistic knowledge of the interaction between cell autonomous (intraneuronal protein aggregation and related sequela) and non-cell autonomous (inflammation and glial response to αSyn accumulation) pathways in α-synucleinopathies can lead to potential disease-modifying immunobiotherapies.

While there are excellent reviews that capture this complex interaction of immunity in α-synucleinopathies [4, 27], very little is known about how astrocytes specifically are involved in this process. In the next sections, we focus specifically on the role of astrocytes in the pathogenesis of α-synucleinopathies by examining the literature on interaction between pathologic αSyn and astrocytes.

Astrocytes: role in homeostasis and diseased brain

Astrocytes are the most numerous cell type in the brain; these "star" shaped cells use their thin processes to directly ensheath up to two million synapses each for the purpose of maintaining synaptic function [3]. At the synapse, astrocytes shuttle ions, neurotransmitters, and other species across their membranes to ensure optimal conditions for neurotransmission. Their additional functions include protection against metabolic and oxidative stress, nutrient transport across the blood brain barrier, production of a quasi-lymphatic system draining waste into the CSF, resolution of neural injury via glial scar formation, and even higher executive functions related to synaptic plasticity [47, 166]. Impairment of these processes is evident in post-mortem brains of neurodegenerative proteinopathies in general, with preclinical studies further suggesting that loss of astrocytic support may play a

direct causal role in the neurodegeneration in these diseases [86, 120].

Astrocytes are a heterogenous group of cells that arise from neural stem cells controlled by complex series of developmental cues, many of which are still undetermined [107]. Broadly, there are two classes of astrocytes—protoplasmic astrocytes found in grey matter and fibrous astrocytes found in the white matter. There are other populations of astrocytes with specialized functions, for example, retinal Muller glia and cerebellar Bergman glia. In the context of α-synucleinopathies, the primary role of astrocytes in relieving oxidative stress, generating neurotrophic factors, modulating inflammation, and reducing pathogenic αSyn have been demonstrated in several preclinical studies, as we will discuss in details in the next sections. Developing the concept of immunoproteostasis, where immunity and αSyn protein homeostasis pathways are continually interacting with each other, we can envision a double-edged sword scenario where this interaction can result in harmful or beneficial outcomes. Further, it can be argued that intraneuronal Lewy bodies are relatively harmless [88] and are a simple measure of cellular response to proteostasis imbalance [39], whereas the inappropriate astrocyte response to these dysfunctional neurons is what drives the inexorable pathological sequela including synaptic failure, neuronal death and clinical symptoms. This is consistent with recently described, though controversial, paradigm called gliotransmission by which neuronal activity induces astrocytes to secrete neuroactive substances into the synaptic cleft that might ultimately regulate brain organ health. It is also tempting to speculate that the subcellular localization of αSyn aggregates within astrocytes, compared to intraneuronal αSyn found within LBs and GCIs, may result in a new form of αSyn with unique properties such as different aggregation potential, prion-like conformational templating, and toxicity. Such unique forms or αSyn 'strains' are increasingly being recognized as important determinants of disease pathogenesis [118, 121]. Another factor to consider is that the inherent heterogeneity in astrocytes (regional, developmental and functional; [78]) may play a role in generation of different αSyn strains, leading to specific disease progression scenarios in the brain. In the next sections, we will discuss the implications of these hypotheses and further introduce some recent paradigms that can have critical impact on therapeutic strategies.

Astrocytic αSyn inclusions are distinct from intraneuronal Lewy pathology

Aggregated αSyn has been reported in astrocytes of PD, DLB and MSA patients [79, 145] (Fig. 1). On the whole, post-mortem studies show that the distribution of astrocyte αSyn pathology closely mirrors the appearance of

intraneuronal LB pathology in the temporal and insular cortex in PD and DLB patients [22, 52]. In PD and DLB patients, most of the aggregated αSyn is observed in astrocytes in the grey matter and in Bergman glia [110, 124], particularly in areas such as the temporal lobe, limbic areas, cortex and substantia nigra (Table 1). These astrocytic αSyn inclusions are characteristic of PD and DLB and are rarely observed in MSA while being absent in other dementias and healthy controls (Table 1). Some studies have reported at least 60–100+ αSyn-positive astrocytes within a single unilateral section from the midbrain or cortex of PD/DLB or other α-synucleinopathy patients, which was comparable to the levels of intraneuronal LB pathology within the same field of interest [22, 66, 160, 168, 177]. The presence of αSyn-positive astrocytes largely paralleled both the location and severity of neuronal LBs within the cortex or midbrain as noted by five studies examining LBD or PD cases [22, 66, 141, 145, 168]. In many cases, these astrocytes do not show hypertrophic morphology as would be expected in a typical reactive state, but instead are characterized as having many fine radiating processes [145, 159, 160, 168, 169]. In comparison with MSA where astrocytic αSyn is sparse but there is widespread gliosis [74], the presence of αSyn-laden but non-reactive astrocytes in DLB/PD may suggest that the accumulated αSyn is impairing glial response. These astrocytic αSyn inclusions are ultrastructurally different from the typically densely packed neuronal LB pathology; astrocytic αSyn is diffusely distributed through the cell body and processes, with granular staining pattern reminiscent of vesicles or lysosomes [22]. Moreover, unlike the neighboring neurons with LBs that are readily characterized by H&E histology, silver staining or phosphorylated Serine 129 (pSer129)-αSyn immunoreactivity, astrocytic LBs do not share these histological properties. Indeed, the most critical roadblock in these post-mortem analyses appears to be accessing and identifying the specific αSyn species, especially when using formalin-fixed and paraffin-embedded human brain sections. A clear breakthrough was achieved when using antibodies to the central domain of αSyn, several groups could successfully demonstrate αSyn inclusions in astrocytes of PD/DLB patients (Table 1) [22, 87, 156, 160, 177] . In addition, because of epitopes being potentially masked or modified in fixed brain tissues, astrocytic αSyn can be visualized only after using harsh antigen retrieval methods. Several studies used formic acid pretreatment to uncover epitopes in the central portion of αSyn (including the NAC domain) that seem to be specifically present in astrocytic αSyn inclusions in PD/DLB patients, but absent in MSA patients or controls (Table 1) [22, 66, 87, 93, 141, 145, 156, 160, 177]. These same studies observed that there was little to no labeling of astrocytic αSyn when N or C-terminal antibodies against αSyn were used, or when formic acid pretreatment was excluded [22, 87, 156, 160, 177]. This pattern was not seen

with neuronal αSyn aggregates where all antibodies seemed to detect LBs equally [22, 87, 156, 160, 177]. Further, while neuronal LBs are typically negative for Gallyas–Braak silver staining, astrocytic αSyn inclusions were reported to be reactive to Gallyas–Braak silver in a few studies [159, 160, 168, 169] (Table 1). In addition to being unreactive to N- and C-terminal αSyn antibodies, astrocytic αSyn does not colocalize with p62/SQSTM1 or ubiquitin, as is commonly observed with neuronal LBs [22]. Collectively, these data suggest that astrocyte-resident αSyn may have unique ultrastructure and have extensive modifications, including post-translational modifications such as truncation. Such unique structural properties of astrocytic αSyn can have consequences relating to αSyn aggregation and prion-like transmission properties.

Based on the cumulative findings of the aforementioned studies, we generated a monoclonal antibody raised against the central portion of αSyn (antibody 3H11; residues 43–63 of αSyn abutting the NAC) and used it to demonstrate robust astrocyte-resident αSyn pathology in two DLB cases following antigen retrieval using formic acid (Fig. 1a–c). In these DLB cases, dense astrocytic αSyn was particularly prominent in limbic structures of the temporal lobe such as the hippocampus and amygdala, where double labeling using the GFAP antibody with the 3H11 antibody confirmed the finding (Fig. 1c). This astrocytic αSyn is thought to be pathologic in nature, as no astrocytic αSyn staining was detected in the hippocampus of an Alzheimer's case (Fig. 1f). Interestingly, by immunoblotting, 3H11 antibody recognized different PD-associated αSyn mutants differentially, indicating that some of these mutations disrupts the 3H11 epitope in αSyn (Fig. 1i–j). We observed αSyn reactive astrocytes not only in the direct vicinity of cortical LBs, but even extending further into the parenchyma where the majority of αSyn reactive cells appear to be astrocytes (Fig. 1a). Whether astrocytic αSyn accumulation precedes the development of cortical LBs is still unknown but knowledge about the temporal aspect of cellular vulnerability to pathological αSyn will inform us on the etiology of α-synucleinopathies, including the prion-like properties of αSyn. Whether 3H11-immunoreactive astrocyte inclusions in the enteric or central nervous system track with the Braak pathological staging [23] will need to be empirically determined to understand how astrocytes contribute to αSyn pathogenesis. One feasible theory is that astrocytes initially function as scavengers of extracellular pathologic αSyn preceding the formation of neuronal LBs. It is possible that astrocytes containing these pathologic αSyn, having processes extending to hundreds of thousands of synapses, can subsequently contribute to spreading of αSyn fibrils themselves. This will be elaborated in subsequent sections.

In rodent transgenic models of α-synucleinopathy, αSyn immunoreactivity has been readily observed in neurons

Table 1 Astrocytic αSyn inclusions: a brief review of literature

No of subjects with astrocyte inclusions (total #)	Location of astrocyte inclusions	Antigen Retrieval	αSyn antibody (astrocyte labeling)	Comments	Reference
24 (30) PD 0 (7) iLBD 0 (30) control	13/24 SNpc 24/24 midbrain/pontine tegmentum	NA	Polyclonal αSyn (114–131) (+)	Number of positive astrocytes parallels severity of LBs Amount of astrocyte inclusions correlated with neuronal loss Double labeling with GFAP and vimentin to identify astrocytes	[168]
8 (8) DLB	8/8 temporal lobe 8/8 frontal cortex 7/8 basal ganglia 6/8 midbrain/pontine tegmentum 5/8 SNpc	FA	αSyn NAC 60–75 (+) αSyn N-terminal 1–15 (−) αSyn C-terminal 108–122 (↔)	"Star like astrocytes" with α-syn positivity throughout perikarya and processes Densest amount of α-syn positive astrocytes in temporal lobe with 100–200 SLA within visual field	[160]
x (7) PD x (5) DLB 0 (6) MSA 0 (25) other disease 0 (15) control	PD, DLB : cerebral cortex, basal ganglia	FA	αSyn N-terminal 1–15 (+) αSyn NAC 60–75 (+) αSyn 110–140 (+)	More positive astrocytes in DLB compared with PD Number of positive astrocytes parallels severity of LBs Grey matter astrocyte staining only	[141]
9 (9) LBVAD 2 (2) DLB 1 (1) PD 0 (17) other disease 0 (4) control	PD, DLB, LBVAD (distinction not made): neocortex, hippocampus	FA	αSyn N-terminal 1–9 (−) αSyn NAC 61–75 (+) αSyn C-terminal (101–110 and 131–140) (−)	Grey matter and cortical astrocyte staining Astrocyte inclusions tau negative	[156]
10 (10) PD 0 (2) iLBD 0 (5) control	10/10 striatum 10/10 SNpc 10/10 midbrain and pontine tegmentum 8/10 cingulate and other cortex	HCl	Polyclonal αSyn full-length (+)	60+ glial inclusions per area in cingulate compared with 50+ LBs in same area Glial inclusions correlate with neuronal loss and severity of LB	[66]
14 (14) PD 0 (6) control	14/14 cortex 12/14 striatum 11/14 thalamus	FA	αSyn NAC 91–99 (+) αSyn C-terminal 116–131 (−)	Astrocytic staining parallels severity of LB pathology No correlation between plaques and astrocytic inclusions Astrocytic staining is diffuse and granular throughout cell Densest in temporal lobe	[22]
0 (10) PD 0 (8) DLB 0 (9) other disease 0 (3) control	N/A	NA	αSyn N-terminal 1–15 (−)	Silver-positive glial inclusions in all PD and DLB cases most abundant in SN	[7]

Table 1 (continued)

No of subjects with astrocyte inclusions (total #)	Location of astrocyte inclusions	Antigen Retrieval	αSyn antibody (astrocyte labeling)	Comments	Reference
17 (20) PD 0 (26) other disease 0 (30) control	8/17 SNpc 17/17 other midbrain region	NA	No antibodies used	Silver-positive, tau-negative inclusions in astrocytes in PD Positive astrocytes had many fine radiating argyrophilic tendrils; differ from tufted astrocytes of PSP 20+astrocyte inclusion in one unilateral PD midbrain section Not correlated with amount of remaining neurons or LBs in SN	[169]
6 (15) MSA 0 (20) DLB 0 (20) control	3/6 periventricular astrocytes in cerebrum 6/6 subpial astrocytes in midbrain, brainstem 1/6 bergmann glia in cerebellum	NA	αSyn pSer129 (+)	Amount of positive astrocytes correlated with MSA of longer duration	[110]
1 (1) PD (fetal transplant)	Within fetal transplant	NA	αSyn pSer129 (↔)	Glial inclusions throughout the graft and outside the transplant region	[2]
6 (8) DNTC 0 (6) control	6/6 temporal lobe most densely within entorhinal cortex	FA	αSyn N-terminal 1–15 (−) αSyn NAC 60–75 (+) αSyn 108–122 (−)	α-syn pathology confined to temporal lobe Semiquantitative comparison indicated near equivalent levels of astrocytic and neuronal α-syn pathology	[177]
4 (6) PD 5 (7) DLB 3 (7) MSA 0 (5) control	PD, DLB, MSA: 12/12 bergmann glia molecular layer cerebellum	NA	αSyn C-terminal 114–131 (+)* αSyn full-length (+)*	LB like inclusions and doughnut shaped structures; also detectable by H&E No correlation between Bergmann glia α-syn positivity and disease outcome	[124]
x (34) PD/DLB x (14) MSA 0 (x) Control	PD,DLB: Temporal lobe, cingulate cortex	FA	αSyn N-terminal 46–53 (+)	Tissue microarray analysis	[87]
13 (13) PD 0 (29) MSA 0 (44) other disease 0 (13) control	13/13 subcortical grey matter	FA	αSyn 15–123 (+) αSyn full-length (+)	40–45% of subcortical astrocytes in PD accumulated α-syn α-syn-positive astrocytes and neurons localized in same regions Protoplasmic astrocytes affected more than fibrous astrocytes	[145]

Additional studies have noted glial reactivity for αSyn in PD/DLB, however, the lack of differentiation between microglia, astrocytes, and oligodendrocytes led to them being omitted from this Table

+ positive staining, − negative staining, ↔ weak staining, x, n number not specified, NA information not available

*Labeled Bergman Glia only

as well as astrocytes [82, 132, 133, 146, 148] (Fig. 2), albeit more frequently than observed in human AD/DLB cases. These astrocytic inclusions even occur when αSyn is expressed under a neuronal promoter ((Thy-1)-human [A30P] αSyn), suggesting that αSyn can probably be internalized by astrocytes and subsequently accumulate [97]. An important difference between these mouse models and human disease is that full-length aggregated αSyn is detectable in mouse astrocytes even without formic acid pretreatment, although it remains to be seen whether different pre-treatment(s) would uncover additional novel pathologies in mice. Therefore, these transgenic mouse models likely represent a mix of features from both PD/DLB and MSA, but overall, they may prove useful in investigating differential evolution of inclusions in astrocytes compared with neurons.

Astrocytic αSyn pathology: questions on its origin and fate

The etiology and functional consequence of astrocytic αSyn remains unresolved. The field is generally constrained by a lack of systems-level insights into neuronal function and cell type-specific gene expression patterns that can shed light into astrocyte-mediated functional impairment, neurodegeneration and symptomatic progression of PD/DLB. A critical question in this context is whether astrocytes facilitate removal of toxic αSyn by phagocytosis [53] or do astrocytes directly contribute to the increasing neuronal proteostasis via uptake and subsequent prion-like propagation of the phagocytosed pathologic material? The latter premise that astrocytes can facilitate αSyn transmission comes from a transgenic mouse line that overexpresses human A53T αSyn from the astrocyte-specific GFAP promoter (GFAP-tTA/tetO-α-syn mice). In these mice, diffuse intraneuronal LBs are observed throughout the CNS suggesting that astrocyte to neuronal spread of pathologic αSyn had taken place [64]. Some plausible theories behind the origin of astrocytic αSyn pathology are (1) phagocytic or pinocytotic uptake of extracellular αSyn; (2) direct transfer from neurons through an active process, such as tunneling nanotubes or exosomal transfer or (3) de novo induction of αSyn pathology during pathogenesis. In this section, we will discuss the literal yin–yang of astrocyte scavenger function vis-à-vis its role in propagation of αSyn pathology.

Several in vitro studies have reported that astrocytes can rapidly ingest extracellular αSyn, within minutes of being exposed [25, 33, 83, 97]. All of these studies concluded that astrocytes internalize pathologic αSyn more readily than neurons, suggesting that astrocytes are primed to scavenge DAMPs, such as αSyn conformers. In vivo evidence of this phenomenon was reported in mice where overexpression

of αSyn under neuronal Thy-1 or PDGFβ promoters (A30P αSyn and wild-type αSyn, respectively) resulted in increased astrocytic αSyn, presumably following endocytosis from extracellular sources [93, 97]. Following endocytosis, the αSyn can be subsequently trafficked to the lysosomes [93, 97]. The process of αSyn internalization and cellular trafficking is thought to be different between neurons, microglia and astrocytes, which suggests that this might potentially lead to formation of unique αSyn conformers within different cell types. Neurons can internalize αSyn by interacting with cell surface heparin sulphates [67] or specific receptors such as Lag3 [100] or Na^+/K^+ transporting ATPase subunit α3 [142], following which it can be either transported along microtubules as naked proteins or inside vesicles into the lysosomes. Microglia can engulf αSyn using TLR4 [53], resulting in NFκB activation, release of pro-inflammatory cytokines and production of reactive oxygen species. Astrocytes, however, do not seem to require TLR4 for αSyn phagocytosis [53]. Further, astrocytes seem to process endocytosed αSyn differently than neurons, as shown by a unique interactome revealed by mass spectrometry [143] and presence of partial breakdown products of αSyn that are reactive specifically to αSyn central domain antibodies (Fig. 1, Table 1). It is possible that extracellular αSyn is cleaved by matrix metalloprotease MMP3 before astrocytic phagocytosis or processed by lysosomal cathepsins after ingestion, leading to generation of truncated species [125, 152]. In vitro studies have shown αSyn aggregation follows different kinetics at normal pH (7.4) and at acidic pH (typically found in lysosomes and endosomes). At pH values below 6, αSyn aggregation is predominantly triggered via secondary nucleation changes (such as fragmentation and surface-assisted nucleation) rather than a simple elongation process [30]. Such secondary nucleation processes can lead to faster multiplication of aggregates and presumably aggravate disease pathogenesis. Therefore, endosomal trafficking of αSyn may result in an exacerbated neurotoxic phenotype since C-terminal truncated αSyn is known to fibrillize more rapidly than full-length variants and cause more cytotoxicity [147].

Astrocytes and neurons are capable of undertaking bidirectional or unidirectional intercellular transport of αSyn through various mechanisms [167]. Both in vitro and in vivo studies have shown the presence of tunneling nanotubes (TNT) that can transfer αSyn between neurons and astrocytes [1, 46, 130]. TNTs are thin (50–200 nm in diameter), actin-rich membranous channels that can connect the cytoplasms of cells as far apart as 100 μm. Lysosomal resident αSyn can traverse between neurons [1] or more intriguingly, stressed astrocytes with defective lysosomal function can incidentally transfer 'undigested' αSyn with a healthy astrocyte while acquiring healthy functional mitochondria from the healthy astrocyte [130]. This could result in a

Fig. 2 Robust astrogliosis and astroglial αSyn accumulation in transgenic mouse models of α-synucleinopathy. **a** Immunofluorescent detection of GFAP in spinal sections from M83$^{+/-}$ transgenic mice overexpressing human [A53T] αSyn that were intramuscularly injected with preformed wild-type mouse αSyn fibrils. In this model, pSer129-αSyn pathology and motor neuron death is apparent at 2 months post-injection, whereas increase in GFAP, representative of astrocyte activation, is observed at later time points. **b** Immuno- fluorescent detection of GFAP (green) and pSer 129 αSyn (red) in the spine of terminal M83$^{+/-}$ transgenic mice described in **a**; in regions of neuronal death, astrocytes closely interact with extracellular aggregated αSyn. **c** Immunofluorescent detection of GFAP (green) and pSer 129-αSyn (red) in the midbrain of M20 transgenic mice overexpressing human αSyn that were seeded with preformed αSyn fibrils in the striatum showing the presence of abundant astrocytic αSyn pathology

double-edged sword scenario: infection of healthy astrocytes with potentially toxic αSyn conformers leading to prion-like transmission and functional recuperation of αSyn-damaged astrocytes with fresh mitochondria. Another mode of intercellular communication is through exosomes. Exosomes are small (40–100 nm) vesicles that originate from multivesicular bodies of the endocytic pathway of neurons, astrocytes and microglia and are thought to be involved in clearance of cell-derived debris [29]. αSyn-carrying exosomes can readily cause neuronal death in vitro [50]. Recent data also show that brain-derived exosomes from DLB patients contain pathologic αSyn that can be internalized by both neurons and astrocytes leading to increased pathogenicity in mouse brains [112]. Interestingly, exosomal αSyn release is not reduced by blocking ER–Golgi transport mechanism, suggesting that αSyn containing exosomes can be extruded through non-conventional pathways [65, 71], such as exosome-associated exocytosis and/or exophagy [49]. Thus, so far, the data suggest that uptake of exosomes or vesicular

αSyn by astrocytes can potentially have detrimental effects on disease pathogenesis in α-synucleinopathies by allowing transcellular propagation of pathologic αSyn and altering astrocyte homeostasis.

Among these theories, the last one, i.e., reactive de novo aggregation of αSyn is not fully supported by direct experimental evidence in vivo. αSyn immunoreactive protoplasmic astrocytes have been found in abundance in human brain regions typically devoid of LB, such as striatum and dorsal thalamus [22] which anecdotally supports this theory. However, the amount of endogenous αSyn protein that is typically expressed by glia is far less than what would be expected to be needed for successful de novo templated aggregation and transmission of pathology. In the healthy brain, αSyn is detectable in white matter astrocytes following immunohistochemical staining; however, this occurs only at very low levels and the tissue must be extensively pre-treated [108]. Immuno-EM studies have shown that the subcellular distribution of αSyn in these astrocytes tend to

be diffuse throughout the cell body and processes and remain in association with mitochondrial membranes, ribosomes, and small vesicles [108]. In vitro evidence from astrocytic cell lines showed that only small amounts of αSyn can be detected by both mRNA and protein assays [158]. Interestingly, later studies have shown a clear association between upregulation of synuclein levels and astrocyte activation status, at least in vitro. For example, αSyn is upregulated in cultured astrocytes when exposed to inflammatory cytokines [158] or during oxidative stress [37]. Therefore, although upregulation of endogenous astrocytic αSyn may contribute to disease, it is more likely that the majority of αSyn found within astrocytes in the diseased brain is mostly derived from neuronal origins.

Functional consequences of astrocytic αSyn: lessons from in vitro studies and transgenic animal models

The belief that astrogliosis is a passive bystander response to increasing intraneuronal αSyn proteostasis and the neurodegenerative cascade is now under debate. Recent data showing that astrocytes can actively communicate with neurons and alter neuronal plasticity and homeostasis has been critical in establishing the hypothesis that astrocytes may be more directly involved in αSyn pathogenesis [61].

The function of endogenous αSyn within normal astrocytes is unclear, although there is some evidence that αSyn is involved in astrocytic fatty acid metabolism [32]. However, later studies have shown a clear association between upregulation of synuclein levels and astrocyte activation status, at least in vitro [37, 158]. Although upregulation of endogenous astrocytic αSyn may contribute to disease, it is more likely that the majority of αSyn found within astrocytes in the diseased brain is derived from neuronal origins, as has been discussed in the previous section. Studies in PD brains have shown that midbrain astrocytes undergo apoptosis in addition to nigral neurodegeneration [73, 85, 106], suggesting that non-cell autonomous events have a profound effect on the neurodegenerative cascade. In cultures treated with pathologic αSyn or human brain-derived LBs, astrocytes display morphological changes consistent with activation, as well as mitochondrial fragmentation, autophagic impairment, impaired Ca^{2+} flux, sensitization to oxidative stress and death [6, 25, 33, 64, 83, 97, 104, 149]. The mechanism by which aggregated αSyn induces toxicity in astrocytes appears to be through a combination of mitochondrial dysfunction and impaired autophagy and mitophagy leading to oxidative stress and apoptosis, as demonstrated by in vitro studies (Fig. 3) [25, 33, 51, 97]. It is possible that several familial PD risk genes that lead to Parkinsonism without necessarily causing αSyn accumulation have important roles

in mitochondrial function and oxidative stress, suggestive of commonalities in etiology of Parkinsonian syndromes (Fig. 3).

In animal models, neuronal overexpression of human αSyn or injection of human brain materials leads to astrocyte activation, as evident by increased GFAP, S100β or vimentin immunoreactivity (reviewed in [84]). In a peripheral to central transmission model of αSyn pathology expressing human [A53T] αSyn from prion promoter [Line M83; B6;C3-Tg(Prnp-*SNCA**A53T)83Vle/J], we observed motor neuron death and pSer129-αSyn pathology prior to the appearance of astrogliosis (Fig. 2a) [132, 148] as in human PD where astrocytic hyperactivation usually follows nigral degeneration [163]. Intriguingly, in Line M83 mice, we observed widespread nigral astrocytic pSer129-αSyn pathology while sparing the dopaminergic neurons following intracranial seeding of αSyn aggregates (Fig. 2c). Therefore, the relationship between astrocytic αSyn toxicity and neuronal dysfunction remains unclear. This aspect was also investigated in transgenic mice expressing αSyn exclusively from astrocytes. In an inducible transgenic mouse model expressing human [A53T] αSyn specifically from astrocytes (GFAP-tTA/tetO-α-syn line), extensive astrocytic death, mitochondrial dysfunction and dopaminergic neurodegeneration were observed [64]. However, another transgenic model with dramatic levels of astrocytic expression of αSyn (human [A30P + A53T] αSyn driven by chicken β actin promoter; BAsyn/PaKO line) did not show overt neurodegeneration in the substantia nigra but had profound motor deficits, suggesting that impairment of astrocytes can lead to neuronal dysfunction even without overt cell death [104]. Interestingly, a specific subtype of astrocyte, A1 astrocyte, has been identified in the nigra of PD patients [95] and a prion promoter-driven human [A53T] αSyn transgenic mouse model (C57BL/6; Prnp-*SNCA**A53T [178]) that has been postulated to drive neurodegenerative cascade in α-synucleinopathies. These A1 astrocytes are devoid of their usual ability to promote neuronal outgrowth, synaptogenesis and phagocytosis, and further can lead to death of neurons and oligodendrocytes. In addition, blocking the formation of these reactive astrocytes leads to elongation of life in the human [A53T] αSyn mouse model of α-synucleinopathy [178]. Overall, though the A1/A2 characterization of astrocyte functionality has provided a simplistic and convenient platform for initiating our understanding into astrocyte involvement in α-synucleinopathies, future transcriptomic and functional studies should be conducted to reveal physiologically relevant disease-associated profiles that can shed light on astrocyte heterogeneity and selective vulnerability in α-synucleinopathies.

Recent work has illuminated that one of the pathways underlying the stereotypical spread of αSyn pathology is by prion-like transmission of αSyn in transgenic mouse

Fig. 3 αSyn mediated alterations in neuro-glial homeostasis in health and disease. Accumulation of αSyn leads to Lewy pathology through a variety of cellular processes. In neurons and astrocytes, αSyn has been implicated in dysfunction of lysosomes (LYS) and mitochondria (MITO), which enhances ROS production and toxic sequela. Neuronal αSyn can be transported into neighboring astrocytes via tunneling nanotubes (TNT), receptors such as Toll-like receptors (TLR), or several indirect methods such as internalization of exocytosed material from the synaptic space. We hypothesize that astrocytic lysosomes preferentially cleave full-length αSyn into smaller toxic truncation products that might have additional pathological functions with astrocytes. Toxic accumulation of αSyn within astrocytes may damage their normal functions and have adverse results such as synaptic accumulation of neurotransmitters including glutamate and dopamine (DA) that are in part cleared by astrocytes through EAAT2 and DAT/NET, respectively. Astrocytes normally protect against oxidative stress in the CNS through production of multiple products including ARE factors, KEAP1/NFR2, Glutathione, NURR1 and NQO1; loss of these factors due to toxic accumulation of αSyn may contribute to neurodegeneration. Astrocytic uptake of αSyn and oxidative stress may impinge on the NF-κB pathways that can result in increased inflammatory cytokines, such as IL-6 or TNFα that will affect the function of neighboring microglia or peripheral immune cells which represents another modality by which astrocytes may contribute to neurodegeneration. Additionally, common risk factor genes such as DJ-1, Parkin and Pink1 are highly expressed in astrocytes and their dysfunction may affect mitophagy in a parallel pathway to that of toxic αSyn resulting in similar degenerative features. Red arrows denote pathological processes, green arrows denote putative therapies or beneficial pathways and black arrows denote normal physiological processes

models of α-synucleinopathy injected with αSyn fibrils or disease-associated brain extracts (reviewed in [165]). While some groups reported mostly intraneuronal αSyn pathology during this transmission process in human [A53T] αSyn transgenic mice [99], other groups including ours reported robust astrocytic αSyn pathology in these mice suggesting that astrocytes can also contribute to αSyn transmission [131, 146, 148]. Interestingly, we observed that the majority

of the pathological αSyn in the substantia nigra of these mice were localized to astrocytes, and none to dopaminergic neurons (Fig. 2c). This might imply that astrocytes can modify disease pathogenesis in this transmission model either by scavenging and having a neuroprotective function or as an unwitting accomplice in αSyn pathogenesis. Other groups have shown that astrocytes can take up these αSyn assemblies and direct these to lysosomes for degradation in organotypic slice cultures from wild-type mice [98], though chronic uptake may also lead to cellular damage and inclusion formation in primary cultures [97]. Importantly, whether astrocyte-resident pathological αSyn has unique strain-like properties distinct from neuronal αSyn inclusions, as observed in primary astrocytes in vitro [131], remains a matter of debate [103].

Astrocytes can protect dopaminergic neurons by improving mitochondrial function [48] and simultaneously can also regulate αSyn pathogenesis in the synaptic clefts [97]. Additionally, astrocytes participate in dopamine metabolism through uptake from the synaptic cleft [157] and impairment of this process may lead to increased cellular stress through build-up of reactive dopamine products [105, 173]. However, whether astrocytic processes can potentially modulate clinical symptoms by regulating formation and clearance of dopamine–αSyn adducts or αSyn induced dopamine oxidation in the extrasynaptic space, remains to be investigated.

Cumulatively, the current evidence suggests that various pathologic forms of αSyn are toxic to astrocytes through a pathway incorporating impaired autophagy and resulting mitochondrial dysfunction from what may be mitophagy dysregulation [51]. Overall, an idea that is supported by clinical and preclinical evidence is that pathologically modified forms of αSyn may slowly accumulate in astrocytes following passive uptake or through some form of extrusion from neurons. Ultimately, this might reach a threshold where astrocytes are too impaired to respond to toxic build-up of LB pathology. One might speculate that αSyn overload of astrocytes would theoretically result in the loss of the preferential uptake of αSyn by astrocytes causing a shift towards trans-synaptic propagation and microglial involvement which would lead to dysfunctional immune function and worsening of disease.

Gliotransmission in α-synucleinopathies: possible co-morbid factor in αSyn pathogenesis

Metabolic exchanges across the astrocyte–neuron synapses or tripartite synapses are critical in maintaining CNS homeostasis [123]. Astrocytes are responsible for scavenging glutamate from the synaptic cleft as well as supplying lactate for neuronal activity through a process called gliotransmission. αSyn, being an abundant pre-synaptic protein, can potentially alter the function of the tripartite synapse formed between astrocytes and the pre- and post-synaptic densities. Recent studies have reported toxic gain of function of αSyn at the synapse by redistribution of SNARE protein, affecting dopamine transporter function and increasing glutamate excitotoxicity [17, 58, 136]. Overexpression of human [A53T] αSyn in the GFAP-tTA/tetO-α-syn transgenic mice led to reduced glutamate transporter expression from the astrocytes, suggesting a direct role of αSyn in neurometabolic coupling to astroglia [64]. Whether this altered gliotransmission plays a role in αSyn pathogenesis remains an intriguing premise that needs to be validated in preclinical mouse models, but could be a modality by which impaired astrocytes potentially contribute to clinical symptoms (Fig. 3).

Astrocyte function can be altered by PD-associated genetic risk factors

Aside from *SNCA*, several other genes have been identified to be key risk factors in PD (reviewed in [21]). Among these, *PARK2*, *PARK7*, *GBA*, *LRRK2*, *PINK1* and *NR4A2* are expressed from mature astrocytes and unsurprisingly, most of these have been linked to neuroinflammatory response in preclinical models [21]. Therefore, it is possible that aside from disrupting neuronal function, these αSyn variants also compromise astrocyte homeostasis. Some of these gene variants do not necessarily cause αSyn pathology in all patients; however, by regulating mitophagy or redox function, these genes may cause generalized proteostasis imbalance or dysfunctional autophagic response in astrocytes leading to clinical symptoms reminiscent of Parkinsonism [21].

A common major cellular pathways affected by these genes is induction of oxidative stress causing widespread damage to cellular lipids, proteins, and DNA [41, 96, 114]. Indeed, accumulation of reactive oxygen species (ROS) can induce formation of TNTs [182], which has been shown by various groups to be conduits for αSyn propagation between astrocytes and neurons [1, 46, 130]. A homeostatic response of astrocytes to mitigate ROS is by a redox-sensitive decrease in KEAP1-mediated degradation of a transcriptional regulator, Nrf2. This induces expression of anti-oxidant response elements (ARE) leading to expression of detoxification and anti-oxidant enzymes such as glutathione, metallothioneins, NAD(P)H Quinone Dehydrogenase 1 (NQO1) and heme oxygenase. Several preclinical studies have shown a protective effect of Nrf2 on α-synucleinopathy [36, 57, 69, 72, 90, 171]. Interestingly, astrocytic Nrf2 overexpression rescues the phenotype and extends life span of human [A53T] αSyn transgenic mice [57]. This has spurred multiple studies testing

the neuroprotective effects of Nrf2 activators as potential PD therapeutics [44, 56, 76]. Impairment of these protective functions of astrocytes by αSyn accumulation may contribute to neuronal demise, and their restoration could represent avenues for therapeutic development (Fig. 3).

DJ-1 (encoded by *PARK7*) that has been implicated in oxidative stress in PD [20, 155] as well as modulating αSyn aggregation and toxicity in preclinical models [140, 183]. DJ-1 is redox sensor of the cell and upon identifying ROS, it utilizes multiple defense mechanisms including direct neutralization of ROS, stabilization of Nrf2 and increased mitochondrial association [31, 40, 81]. Upregulating DJ-1 reduces αSyn pathology and rescues motor symptoms [181]. Additionally, DJ-1 can physically interact with αSyn to reduce its aggregation propensity [183]. Disease-associated variants of other astrocytic specific genes, such as *PARK2*, *LRRK2* and *GBA1*, lead to increased αSyn pathology in patient-derived induced pluripotent stem cells [68, 113, 174], suggesting a close association between astrocyte homeostasis and αSyn pathogenesis. In spite of reports that PINK1 is absolutely critical for astrogliogenesis [38] and that it phenocopies PARKIN (encoded by *PARK2*) function [8], there are no direct reports associating PINK1 with αSyn pathogenesis.

NURR1/NR4A2, enriched in mouse astrocytes and human microglia, is essential for dopaminergic neuronal development. Mutations in this gene has been linked to familial late-onset PD [92]. The primary function of Nurr1 is to suppress NF-κB, leading to neuroprotection of dopaminergic neurons [134]. A second, more controversial, study showed that Nurr1 can also remediate αSyn toxicity in dopaminergic neurons by stimulating GDNF signaling [43]. Interestingly, Nurr1 was also shown to negatively regulate αSyn transcription [175], suggesting a common link between glial function and αSyn levels.

In PD and DLB, evidence of oxidative stress in areas of neuronal loss is seen in post-mortem samples with increased lipid and protein peroxidation products, and altered expression of anti-oxidants within astrocytes (reviewed in [126]). Inadequate astrocytic production of glutathione, metallothionein 1/2, NQO1, DJ-1 and other ROS neutralizing factors in times of dopaminergic neuronal stress may contribute to their selective neurodegeneration in α-synucleinopathies. Coupled with the possibility that αSyn can induce astrocyte toxicity, the impairment of supportive functions may represent a new dimension for αSyn toxicity. Many of the PD risk genes discussed here function in ROS regulatory pathways within astrocytes, and their loss may herald the onset of Parkinsonism either synergistically with αSyn pathology or in a parallel pathway by causing functional impairment of astrocytes (Fig. 3).

Immune-based biotherapies in α-synucleinopathies

A major unmet need in α-synucleinopathies is the lack of disease-modifying therapies. Clinical and neuropathological heterogeneity in the spectrum of α-synucleinopathies, unclear etiologies, as well as the absence of validated biomarkers present critical challenges regarding the development of effective therapeutics. The two major broad therapeutic approaches that are being currently tested in patients are anti-αSyn immunotherapy (passive as well as active) and small molecule drugs that inhibit αSyn accumulation [28], neither of which directly target astrocyte or innate immune mediators. The fact that astrocytes accumulate αSyn aggregates and may be involved in transmission of α-synucleinopathy opens up possibilities that targeting these specific pathologic inclusions or attenuating their consequences through astroglia-targeted therapies can have disease-modifying effects. However, it is not yet clear how best to harness the immune system towards a beneficial outcome on astrocyte function. In this section, we will first describe the trophic factor therapies that have been used in patient trials, which among many factors, alter neuroinflammation but does not necessarily modulate astrocyte function directly.

In previous clinical trials, several neurotrophic factors (that are produced by astrocytes) were tested as neuroprotective pharmacotherapeutics [150]. Of these, glial cell line-derived neurotrophic factor (GDNF) and Neurturin (NRTN) were well-tolerated in patients but, unfortunately, did not meet predetermined end-points in efficacy. More recently, other neurotrophic factors that can be produced by astrocytes, such as cerebral dopamine neurotrophic factor (CDNF) [91] and mesencephalic astrocyte-derived neurotrophic factor (MANF) [180], have shown promise in preclinical models of α-synucleinopathy. Since the receptors and cellular signaling pathways for many of these neurotrophic factors are relatively unknown, more work needs to be done to forward these into the clinical realm.

Several preclinical strategies that work partly by targeting astrocytes have been recently described. Glucagon-like peptide-1 receptor (GLP1R) agonists have shown efficacy in multiple models of neurodegenerative proteinopathies by modulating mitochondrial biogenesis, suppressing microglial activation and inflammation, enhancing autophagy, and clearance of aggregated proteins. One such GLP1R agonist, NLY01, was shown to be neuroprotective in PD models by specifically regulating NF-κB-mediated inflammatory signaling which is downstream of the GLP-1R/PI3K/AKT pathway [9]. More recently, NLY01 was effective in blocking microglia-mediated conversion of astrocytes to the neurotoxic A1 phenotype in a rodent model of α-synucleinopathy [178]. Indeed, a limited open-label trial and a subsequent

What is the source of astrocytic α-synuclein?

Does a bilateral communication between neurons and astrocytes lead to exacerbated disease?

What is the mechanism of bilateral transmission of αSyn—direct physical contact or passive uptake?

How do the astrocyte-resident PD risk genes lead to proteostasis failure in glia—through direct or non-cell autonomous pathways?

Does astrocytic dysfunction precede αSyn proteinopathy or is the dysfunction a result of neuronal αSyn proteinopathy?

Does astrocytic metabolism of internalized αSyn result in toxic by-products that contribute to disease pathogenesis?

Is restoring astrocytic function sufficient to rebalance proteostasis as a monotherapy?

Fig. 4 Critical outstanding questions

double-blind trial of the GLP1R agonist exenatide appeared to improve motor and cognitive function in PD patients [10, 11].

A direct line of preclinical research targeting astrocyte function was done by using midbrain-derived astrocyte grafts into a rat model of PD. These astrocytes, following grafting into the striatum, resulted in remarkable recovery of dopaminergic neurons, especially in the presence of Nurr1 and Foxa2 co-expression. Through a paracrine pathway, these grafted astrocytes were found to exert marked trophic action on the glutamatergic and GABAergic neurons and stimulate endogenous dopaminergic neurons to secrete dopamine [144]. Such therapies have the potential to be the most effective, as instead of isolating one single astrocytic product for supplementation, this would generate the entire spectrum of trophic factors, anti-oxidant compounds, and other astrocytic protective functions needed to assist neurons for overcoming cellular stresses induced by pathologic αSyn.

Conclusion

Astrocytes are the most predominant glial cells in the brain and play critical roles in neuronal development, neural activity, synaptic transmission and learning and memory. However, their role in the etiology of neurodegenerative α-synucleinopathies is still mostly sheathed in mystery (Fig. 4). Several lines of evidence, neuropathological, functional and genetic, indicate that astrocytes are functionally involved in α-synucleinopathies (Fig. 3). How and why these astrocytes synergize with the evolution of proteostasis failure and heterogeneous clinical symptoms needs to be charted out, along with the contribution that regional astrocyte heterogeneity may play a role in selective neurodegeneration. Interestingly, the underlying mechanisms of astrocytic modulation of α-synucleinopathy may be divergent—in some cases, astrocytic activity may need to be enhanced whereas in others, its pathological function will need to be attenuated based on the context and timing of intervention. The fact that astrocytes are a heterogeneous group of cells, in terms of functionality and region-wide distribution, remains under-appreciated in the field of neurodegenerative α-synucleinopathies. Whether this physiological heterogeneity has a role to play in selective vulnerability of neurons along the spectrum of α-synucleinopathy (PD, DLB, MSA) that might ultimately be informative of the spectrum of clinical heterogeneity seen in the patients also need to be examined. Genetic predisposing factors that alter risk for α-synucleinopathies such as *PARK7*, *GBA*, *LRRK2*, *PINK1* and *NR4A2* may also affect astrocyte function and alter disease etiology through altering redox stress or other pathways (Fig. 3). Whether mining such genetic and risk factor data can enable stratification of patients for personalizing treatment options, based on their unique clinical presentation, should be examined in future therapeutic studies. Current strategies of harnessing immunoproteostasis by either using small-molecule drugs or astrocyte-derived neurotrophic molecules or astrocyte transplantation in combination with

immunotherapy remain intriguing and will have to be tested in multiple models of α-synucleinopathies (Fig. 3). Overall, bilateral interactions or non-cell autonomous interactions between astrocytes and neurons or other glia in specific regions of the brain may provide us insights into neuronal dysfunction and death (Fig. 3). Deeper knowledge of astrocyte biology and its functional alterations will be necessary before we can successfully embark on such disease-modifying therapies in α-synucleinopathies.

References

1. Abounit S, Bousset L, Loria F, Zhu S, de Chaumont F, Pieri L et al (2016) Tunneling nanotubes spread fibrillar α-synuclein by intercellular trafficking of lysosomes. EMBO J 35:2120–2138. https://doi.org/10.15252/embj.201593411

2. Ahn T-B, Langston JW, Aachi VR, Dickson DW (2012) Relationship of neighboring tissue and gliosis to alpha-synuclein pathology in a fetal transplant for Parkinson's disease. Am J Neurodegener Dis 1:49–59

3. Allen NJ, Eroglu C (2017) Cell biology of astrocyte-synapse interactions. Neuron 96:697–708. https://doi.org/10.1016/j.neuron.2017.09.056

4. Allen Reish HE, Standaert DG (2015) Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis 5:1–19. https://doi.org/10.3233/JPD-140491

5. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739–29752. https://doi.org/10.1074/jbc.M600933200

6. Angelova PR, Ludtmann MHR, Horrocks MH, Negoda A, Cremades N, Klenerman D et al (2016) Ca2+ is a key factor in alpha-synuclein-induced neurotoxicity. J Cell Sci 129:1792–1801. https://doi.org/10.1242/jcs.180737

7. Arai T, Uéda K, Ikeda K, Akiyama H, Haga C, Kondo H et al (1999) Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/alpha-synuclein. Neurosci Lett 259:83–86

8. Ashrafi G, Schlehe JS, LaVoie MJ, Schwarz TL (2014) Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin. J Cell Biol 206:655–670. https://doi.org/10.1083/jcb.201401070

9. Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov Today 21:802–818. https://doi.org/10.1016/j.drudis.2016.01.013

10. Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K et al (2017) Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664–1675. https://doi.org/10.1016/S0140-6736(17)31585-4

11. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P et al (2015) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinsons Dis 4:337–344. https://doi.org/10.3233/JPD-140364

12. Baig F, Lawton M, Rolinski M, Ruffmann C, Nithi K, Evetts SG et al (2015) Delineating nonmotor symptoms in early Parkinson's disease and first-degree relatives. Mov Disord 30:1759–1766. https://doi.org/10.1002/mds.26281

13. Barker RA, Williams-Gray CH (2016) Review: the spectrum of clinical features seen with alpha synuclein pathology. Neuropathol Appl Neurobiol 42:6–19. https://doi.org/10.1111/nan.12303

14. Barrenschee M, Zorenkov D, Böttner M, Lange C, Cossais F, Scharf AB et al (2017) Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease. Acta Neuropathol Commun 5:1. https://doi.org/10.1186/s40478-016-0408-2

15. Bartels T, Choi JG, Selkoe DJ (2011) α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477:107–110. https://doi.org/10.1038/nature10324

16. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Arizona Parkinson's Disease Consortium et al (2010) Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119:689–702. https://doi.org/10.1007/s00401-010-0664-3

17. Bellucci A, Collo G, Sarnico I, Battistin L, Missale C, Spano P (2008) Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D$_2$ D$_3$ receptor activation. J Neurochem 106:560–577. https://doi.org/10.1111/j.1471-4159.2008.05406.x

18. Bertoncini CW, Jung Y-S, Fernandez CO, Hoyer W, Griesinger C, Jovin TM et al (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci USA 102:1430–1435. https://doi.org/10.1073/pnas.0407146102

19. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202:17–20

20. Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC et al (2003) DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 24:159–160. https://doi.org/10.1007/s10072-003-0108-0

21. Booth HDE, Hirst WD, Wade-Martins R (2017) The role of astrocyte dysfunction in Parkinson's disease pathogenesis. Trends Neurosci 40:358–370. https://doi.org/10.1016/j.tins.2017.04.001

22. Braak H, Sastre M, Del Tredici K (2007) Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol 114:231–241. https://doi.org/10.1007/s00401-007-0244-3

23. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen-Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197–211

24. Braak H, de Vos RAI, Bohl J, Del Tredici K (2006) Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 396:67–72. https://doi.org/10.1016/j.neulet.2005.11.012

25. Braidy N, Gai W-P, Xu YH, Sachdev P, Guillemin GJ, Jiang X-M et al (2013) Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts. Transl Neurodegener 2:20. https://doi.org/10.1186/2047-9158-2-20

26. Breydo L, Wu JW, Uversky VN (2012) α-Synuclein misfolding and Parkinson's disease. Biochim Biophys Acta Mol Basis Dis 1822:261–285. https://doi.org/10.1016/j.bbadis.2011.10.002

27. Brück D, Wenning GK, Stefanova N, Fellner L (2016) Glia and alpha-synuclein in neurodegeneration: a complex

interaction. Neurobiol Dis 85:262–274. https://doi.org/10.1016/j.nbd.2015.03.003

28. Brundin P, Dave KD, Kordower JH (2017) Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol 298:225–235. https://doi.org/10.1016/j.expneurol.2017.10.003

29. Budnik V, Ruiz-Cañada C, Wendler F (2016) Extracellular vesicles round off communication in the nervous system. Nat Rev Neurosci 17:160–172. https://doi.org/10.1038/nrn.2015.29

30. Buell AK, Galvagnion C, Gaspar R, Sparr E, Vendruscolo M, Knowles TPJ et al (2014) Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation. Proc Natl Acad Sci USA 111:7671–7676. https://doi.org/10.1073/pnas.1315346111

31. Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S et al (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci 101:9103–9108. https://doi.org/10.1073/pnas.0402959101

32. Castagnet PI, Golovko MY, Barceló-Coblijn GC, Nussbaum RL, Murphy EJ (2005) Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice. J Neurochem 94:839–849. https://doi.org/10.1111/j.1471-4159.2005.03247.x

33. Cavaliere F, Cerf L, Dehay B, Ramos-Gonzalez P, De Giorgi F, Bourdenx M et al (2017) In vitro alpha-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains. Neurobiol Dis 103:101–112. https://doi.org/10.1016/j.nbd.2017.04.011

34. Chang D, Nalls MA, Hallgrímsdóttir IB, Hunkapiller J, van der Brug M, Cai F et al (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet 49:1511–1516. https://doi.org/10.1038/ng.3955

35. Chavarría C, Rodríguez-Bottero S, Quijano C, Cassina P, Souza JM (2018) Impact of monomeric, oligomeric and fibrillar alpha-synuclein on astrocyte reactivity and toxicity to neurons. Biochem J 475:3153–3169. https://doi.org/10.1042/BCJ20180297

36. Chen P-C, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW et al (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci USA 106:2933–2938. https://doi.org/10.1073/pnas.0813361106

37. Cheng SY, Trombetta LD (2004) The induction of amyloid precursor protein and alpha-synuclein in rat hippocampal astrocytes by diethyldithiocarbamate and copper with or without glutathione. Toxicol Lett 146:139–149

38. Choi I, Kim J, Jeong H-K, Kim B, Jou I, Park SM et al (2013) Pink1 deficiency attenuates astrocyte proliferation through mitochondrial dysfunction, reduced akt and increased p38 mapk activation, and downregulation of egfr. Glia 61:800–812. https://doi.org/10.1002/glia.22475

39. Chu CT, Zhu J, Dagda R (2007) Beclin 1-independent pathway of damage-induced mitophagy and autophagic stress: implications for neurodegeneration and cell death. Autophagy 3:663–666

40. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP-Y (2006) DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci 103:15091–15096. https://doi.org/10.1073/pnas.0607260103

41. Cobb CA, Cole MP (2015) Oxidative and nitrative stress in neurodegeneration. Neurobiol Dis 84:4–21. https://doi.org/10.1016/j.nbd.2015.04.020

42. Darmanis S, Sloan SA, Zhang Y, Enge M, Caneda C, Shuer LM et al (2015) A survey of human brain transcriptome diversity at the single cell level. Proc Natl Acad Sci USA 112:7285–7290. https://doi.org/10.1073/pnas.1507125112

43. Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Bjorklund A (2012) Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med 4:163ra156. https://doi.org/10.1126/scitranslmed.3004676

44. Denzer I, Münch G, Friedland K (2016) Modulation of mitochondrial dysfunction in neurodegenerative diseases via activation of nuclear factor erythroid-2-related factor 2 by food-derived compounds. Pharmacol Res 103:80–94. https://doi.org/10.1016/j.phrs.2015.11.019

45. Dhillon J-KS, Riffe C, Moore BD, Ran Y, Chakrabarty P, Golde TE et al (2017) A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies. PLoS One 12:e0184731. https://doi.org/10.1371/journal.pone.0184731

46. Dieriks BV, Park TI-H, Fourie C, Faull RLM, Dragunow M, Curtis MA (2017) α-synuclein transfer through tunneling nanotubes occurs in SH-SY5Y cells and primary brain pericytes from Parkinson's disease patients. Sci Rep 7:42984. https://doi.org/10.1038/srep42984

47. Dossi E, Vasile F, Rouach N (2017) Human astrocytes in the diseased brain. Brain Res Bull. https://doi.org/10.1016/j.brainresbull.2017.02.001

48. Du F, Yu Q, Chen A, Chen D, Yan SS (2018) Astrocytes attenuate mitochondrial dysfunctions in human dopaminergic neurons derived from iPSC. Stem cell reports 10:366–374. https://doi.org/10.1016/j.stemcr.2017.12.021

49. Ejlerskov P, Rasmussen I, Nielsen TT, Bergström A-L, Tohyama Y, Jensen PH et al (2013) Tubulin polymerization-promoting protein (TPPP/p25α) promotes unconventional secretion of α-synuclein through exophagy by impairing autophagosome-lysosome fusion. J Biol Chem 288:17313–17335. https://doi.org/10.1074/jbc.M112.401174

50. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH et al (2010) Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 30:6838–6851. https://doi.org/10.1523/JNEUROSCI.5699-09.2010

51. Erustes AG, Stefani FY, Terashima JY, Stilhano RS, Monteforte PT, da Silva Pereira GJ et al (2018) Overexpression of α-synuclein in an astrocyte cell line promotes autophagy inhibition and apoptosis. J Neurosci Res 96:160–171. https://doi.org/10.1002/jnr.24092

52. Fathy YY, Jonker AJ, Oudejans E, de Jong FJJ, van Dam A-MW, Rozemuller AJM et al (2018) Differential insular cortex subregional vulnerability to α-synuclein pathology in Parkinson's disease and dementia with Lewy bodies. Neuropathol Appl Neurobiol. https://doi.org/10.1111/nan.12501

53. Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W et al (2013) Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 61:349–360. https://doi.org/10.1002/glia.22437

54. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS et al (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164. https://doi.org/10.1038/ncb748

55. Fusco G, De Simone A, Gopinath T, Vostrikov V, Vendruscolo M, Dobson CM et al (2014) Direct observation of the three regions in α-synuclein that determine its membrane-bound behaviour. Nat Commun 5:3827. https://doi.org/10.1038/ncomms4827

56. Gan L, Johnson DA, Johnson JA (2010) Keap1-Nrf2 activation in the presence and absence of DJ-1. Eur J Neurosci 31:967–977. https://doi.org/10.1111/j.1460-9568.2010.07138.x

57. Gan L, Vargas MR, Johnson DA, Johnson JA (2012) Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in

the alpha-synuclein mutant (A53T) mouse model. J Neurosci 32:17775–17787. https://doi.org/10.1523/JNEUROSCI.3049-12.2012

58. Garcia-Reitböck P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E et al (2010) SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 133:2032–2044. https://doi.org/10.1093/brain/awq132

59. George JM, Jin H, Woods WS, Clayton DF (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15:361–372

60. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI et al (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985–989

61. Gittis AH, Brasier DJ (2015) Astrocytes tell neurons when to listen up. Science 349:690–691. https://doi.org/10.1126/science.aad0678

62. Goedert M, Masuda-Suzukake M, Falcon B (2017) Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Brain 140:266–278. https://doi.org/10.1093/brain/aww230

63. Gray MT, Gray MT, Munoz DG, Gray DA, Schlossmacher MG, Woulfe JM (2014) Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects. Mov Disord 29:991–998. https://doi.org/10.1002/mds.25779

64. Gu X-L, Long C-X, Sun L, Xie C, Lin X, Cai H (2010) Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol Brain 3:12. https://doi.org/10.1186/1756-6606-3-12

65. Hasegawa T, Konno M, Baba T, Sugeno N, Kikuchi A, Kobayashi M et al (2011) The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α-synuclein. PLoS One 6:e29460. https://doi.org/10.1371/journal.pone.0029460

66. Hishikawa N, Hashizume Y, Yoshida M, Sobue G (2001) Widespread occurrence of argyrophilic glial inclusions in Parkinson's disease. Neuropathol Appl Neurobiol 27:362–372

67. Ihse E, Yamakado H, van Wijk XM, Lawrence R, Esko JD, Masliah E (2017) Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell type. Sci Rep 7:9008. https://doi.org/10.1038/s41598-017-08720-5

68. Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H et al (2012) Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain 5:35. https://doi.org/10.1186/1756-6606-5-35

69. Innamorato NG, Jazwa A, Rojo AI, García C, Fernández-Ruiz J, Grochot-Przeczek A et al (2010) Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One 5:e11838. https://doi.org/10.1371/journal.pone.0011838

70. International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin U-M, Saad M et al (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377:641–649. https://doi.org/10.1016/S0140-6736(10)62345-8

71. Jang A, Lee H-J, Suk J-E, Jung J-W, Kim K-P, Lee S-J (2010) Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem 113:1263–1274. https://doi.org/10.1111/j.1471-4159.2010.06695.x

72. Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernández-Ruiz J, Cuadrado A (2011) Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal 14:2347–2360. https://doi.org/10.1089/ars.2010.3731

73. Jellinger KA (2000) Cell death mechanisms in Parkinson's disease. J Neural Transm 107:1–29. https://doi.org/10.1007/s007020050001

74. Jellinger KA (2018) Multiple system atrophy: an oligodendroglioneural synucleinopathy1. J Alzheimers Dis 62:1141–1179. https://doi.org/10.3233/JAD-170397

75. Jellinger KA, Lantos PL (2010) Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol 119:657–667. https://doi.org/10.1007/s00401-010-0672-3

76. Johnson DA, Johnson JA (2015) Nrf2—a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med 88:253–267. https://doi.org/10.1016/j.freeradbiomed.2015.07.147

77. Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB et al (2015) Colonic bacterial composition in Parkinson's disease. Mov Disord 30:1351–1360. https://doi.org/10.1002/mds.26307

78. Khakh BS, Sofroniew MV (2015) Diversity of astrocyte functions and phenotypes in neural circuits. Nat Neurosci 18:942–952. https://doi.org/10.1038/nn.4043

79. Kim WS, Kågedal K, Halliday GM (2014) Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther 6:73. https://doi.org/10.1186/s13195-014-0073-2

80. Klingelhoefer L, Reichmann H (2015) Pathogenesis of Parkinson disease—the gut-brain axis and environmental factors. Nat Rev Neurol 11:625–636. https://doi.org/10.1038/nrneurol.2015.197

81. Kojima W, Kujuro Y, Okatsu K, Bruno Q, Koyano F, Kimura M et al (2016) Unexpected mitochondrial matrix localization of Parkinson's disease-related DJ-1 mutants but not wild-type DJ-1. Genes Cells 21:772–788. https://doi.org/10.1111/gtc.12382

82. Koller EJ, Brooks MMT, Golde TE, Giasson BI, Chakrabarty P (2017) Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice. Mol Neurodegener 12:1. https://doi.org/10.1186/s13024-016-0142-z

83. Koob AO, Paulino AD, Masliah E (2010) GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with alpha-synuclein. Neurosci Lett 469:11–14. https://doi.org/10.1016/j.neulet.2009.11.034

84. Koprich JB, Kalia LV, Brotchie JM (2017) Animal models of α-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci 18:515–529. https://doi.org/10.1038/nrn.2017.75

85. Kosel S, Egensperger R, von Eitzen U, Mehraein P, Graeber MB (1997) On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol 93:105–108

86. Kovacs GG, Lee VM, Trojanowski JQ (2017) Protein astrogliopathies in human neurodegenerative diseases and aging. Brain Pathol 27:675–690. https://doi.org/10.1111/bpa.12536

87. Kovacs GG, Wagner U, Dumont B, Pikkarainen M, Osman AA, Streichenberger N et al (2012) An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology. Acta Neuropathol 124:37–50. https://doi.org/10.1007/s00401-012-0964-x

88. Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27:1405–1410. https://doi.org/10.1523/JNEUROSCI.4564-06.2007

89. Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38–48. https://doi.org/10.1038/nrn3406

90. Lastres-Becker I, Ulusoy A, Innamorato NG, Sahin G, Rábano A, Kirik D et al (2012) α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum Mol Genet 21:3173–3192. https://doi.org/10.1093/hmg/dds143

91. Latge C, Cabral KMS, de Oliveira GAP, Raymundo DP, Freitas JA, Johanson L et al (2015) The solution structure and dynamics of full-length human cerebral dopamine neurotrophic factor and its neuroprotective role against α-synuclein oligomers. J Biol Chem 290:20527–20540. https://doi.org/10.1074/jbc.M115.662254

92. Le W-D, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG et al (2003) Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 33:85–89. https://doi.org/10.1038/ng1066

93. Lee H-J, Suk J-E, Patrick C, Bae E-J, Cho J-H, Rho S et al (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285:9262–9272. https://doi.org/10.1074/jbc.M109.081125

94. Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L et al (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci USA 102:2162–2167. https://doi.org/10.1073/pnas.0406976102

95. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481–487. https://doi.org/10.1038/nature21029

96. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795. https://doi.org/10.1038/nature05292

97. Lindstrom V, Gustafsson G, Sanders LH, Howlett EH, Sigvardson J, Kasrayan A et al (2017) Extensive uptake of alpha-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage. Mol Cell Neurosci 45:54. https://doi.org/10.1016/j.mcn.2017.04.009

98. Loria F, Vargas JY, Bousset L, Syan S, Salles A, Melki R et al (2017) α-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading. Acta Neuropathol 134:789–808. https://doi.org/10.1007/s00401-017-1746-2

99. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VMY (2012) Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 209:975–986. https://doi.org/10.1084/jem.20112457

100. Mao X, Ou MT, Karuppagounder SS, Kam T-I, Yin X, Xiong Y et al (2016) Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353:3374. https://doi.org/10.1126/science.aah3374

101. Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8:2804–2815

102. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285–1291

103. Melki R (2015) Role of different alpha-synuclein strains in synucleinopathies, similarities with other neurodegenerative diseases. J Parkinsons Dis 5:217–227. https://doi.org/10.3233/JPD-150543

104. Mendritzki S, Schmidt S, Sczepan T, Zhu X-R, Segelcke D, Lübbert H (2010) Spinal cord pathology in alpha-synuclein transgenic mice. Parkinsons Dis 2010:1–9. https://doi.org/10.4061/2010/375462

105. Miyazaki I, Asanuma M (2008) Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama 62:141–150

106. Mochizuki H, Goto K, Mori H, Mizuno Y (1996) Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 137:120–123

107. Molofsky AV, Deneen B (2015) Astrocyte development: a guide for the perplexed. Glia 63:1320–1329. https://doi.org/10.1002/glia.22836

108. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K (2002) Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp Neurol 176:98–104

109. Murray IVJ, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, Ischiropoulos H et al (2003) Role of α-synuclein carboxy-terminus on fibril formation in vitro †. Biochemistry 42:8530–8540. https://doi.org/10.1021/bi027363r

110. Nakamura K, Mori F, Kon T, Tanji K, Miki Y, Tomiyama M et al (2016) Accumulation of phosphorylated α-synuclein in subpial and periventricular astrocytes in multiple system atrophy of long duration. Neuropathology 36:157–167. https://doi.org/10.1111/neup.12243

111. Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K et al (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem 286:20710–20726. https://doi.org/10.1074/jbc.M110.213538

112. Ngolab J, Trinh I, Rockenstein E, Mante M, Florio J, Trejo M et al (2017) Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology. Acta Neuropathol Commun 5:46. https://doi.org/10.1186/s40478-017-0445-5

113. Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P et al (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8:267–280. https://doi.org/10.1016/j.stem.2011.01.013

114. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK et al (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60:759–767

115. Ouberai MM, Wang J, Swann MJ, Galvagnion C, Guilliams T, Dobson CM et al (2013) α-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling. J Biol Chem 288:20883–20895. https://doi.org/10.1074/jbc.M113.478297

116. Outeiro TF, Lindquist S (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302:1772–1775. https://doi.org/10.1126/science.1090439

117. Paillusson S, Clairembault T, Biraud M, Neunlist M, Derkinderen P (2013) Activity-dependent secretion of alpha-synuclein by enteric neurons. J Neurochem 125:512–517. https://doi.org/10.1111/jnc.12131

118. Peelaerts W, Bousset L, Baekelandt V, Melki R (2018) α-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences. Cell Tissue Res 373:195–212. https://doi.org/10.1007/s00441-018-2839-5

119. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M et al (2015) α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522:340–344. https://doi.org/10.1038/nature14547

120. Pekny M, Pekna M, Messing A, Steinhauser C, Lee J-M, Parpura V et al (2016) Astrocytes: a central element in neurological diseases. Acta Neuropathol 131:323–345. https://doi.org/10.1007/s00401-015-1513-1

121. Peng C, Gathagan RJ, Covell DJ, Medellin C, Stieber A, Robinson JL et al (2018) Cellular milieu imparts distinct pathological

α-synuclein strains in α-synucleinopathies. Nature 557:558–563. https://doi.org/10.1038/s41586-018-0104-4

122. Peng C, Gathagan RJ, Lee VM-Y (2018) Distinct α-synuclein strains and implications for heterogeneity among α-synucleinopathies. Neurobiol Dis 109:209–218. https://doi.org/10.1016/j.nbd.2017.07.018

123. Perea G, Navarrete M, Araque A (2009) Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 32:421–431. https://doi.org/10.1016/j.tins.2009.05.001

124. Piao Y-S, Mori F, Hayashi S, Tanji K, Yoshimoto M, Kakita A et al (2003) Alpha-synuclein pathology affecting Bergmann glia of the cerebellum in patients with alpha-synucleinopathies. Acta Neuropathol 105:403–409. https://doi.org/10.1007/s00401-002-0655-0

125. Pieri L, Chafey P, Le Gall M, Clary G, Melki R, Redeker V (2016) Cellular response of human neuroblastoma cells to α-synuclein fibrils, the main constituent of Lewy bodies. Biochim Biophys Acta 1860:8–19. https://doi.org/10.1016/j.bbagen.2015.10.007

126. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J et al (2017) Parkinson disease. Nat Rev Dis Prim 3:17013. https://doi.org/10.1038/nrdp.2017.13

127. Rannikko EH, Weber SS, Kahle PJ (2015) Exogenous α-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes. BMC Neurosci 16:57. https://doi.org/10.1186/s12868-015-0192-0

128. Ravenholt RT, Foege WH (1982) 1918 influenza, encephalitis lethargica, parkinsonism. Lancet (Lond, Engl) 2:860–864

129. Rekas A, Ahn KJ, Kim J, Carver JA (2012) The chaperone activity of α-synuclein: utilizing deletion mutants to map its interaction with target proteins. Proteins 80:1316–1325. https://doi.org/10.1002/prot.24028

130. Rostami J, Holmqvist S, Lindström V, Sigvardson J, Westermark GT, Ingelsson M et al (2017) Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes. J Neurosci 37:11835–11853. https://doi.org/10.1523/JNEUROSCI.0983-17.2017

131. Sacino AN, Brooks M, McKinney AB, Thomas MA, Shaw G, Golde TE, Giasson BI (2014) Brain injection of alpha-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J Neurosci 34:12368–12378. https://doi.org/10.1523/JNEUROSCI.2102-14.2014

132. Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW et al (2014) Intramuscular injection of -synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci 111:10732–10737. https://doi.org/10.1073/pnas.1321785111

133. Sacino AN, Thomas MA, Ceballos-Diaz C, Cruz PE, Rosario AM et al (2013) Conformational templating of α-synuclein aggregates in neuronal-glial cultures. Mol Neurodegener 8:17. https://doi.org/10.1186/1750-1326-8-17

134. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG et al (2009) A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137:47–59. https://doi.org/10.1016/j.cell.2009.01.038

135. Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE et al (2016) Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 167:1469–1480. https://doi.org/10.1016/j.cell.2016.11.018

136. Sarafian TA, Littlejohn K, Yuan S, Fernandez C, Cilluffo M, Koo B-K et al (2017) Stimulation of synaptoneurosome glutamate release by monomeric and fibrillated α-synuclein. J Neurosci Res 95:1871–1887. https://doi.org/10.1002/jnr.24024

137. Sato H, Kato T, Arawaka S (2013) The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's

disease: a review of in vivo models. Rev Neurosci 24:115–123. https://doi.org/10.1515/revneuro-2012-0071

138. Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E et al (2015) Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 30:350–358. https://doi.org/10.1002/mds.26069

139. Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D et al (2009) SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 65:610–614. https://doi.org/10.1002/ana.21685

140. Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A (2004) DJ-1 is a redox-dependent molecular chaperone that inhibits α-synuclein aggregate formation. PLoS Biol 2:e362. https://doi.org/10.1371/journal.pbio.0020362

141. Shoji M, Harigaya Y, Sasaki A, Uéda K, Ishiguro K, Matsubara E et al (2000) Accumulation of NACP/alpha-synuclein in Lewy body disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 68:605–608

142. Shrivastava AN, Redeker V, Fritz N, Pieri L, Almeida LG, Spolidoro M et al (2015) Synuclein assemblies sequester neuronal 3-Na+/K+-ATPase and impair Na+ gradient. EMBO J 34:2408–2423. https://doi.org/10.15252/embj.201591397

143. Shrivastava AN, Redeker V, Fritz N, Pieri L, Almeida LG, Spolidoro M et al (2016) Data in support of the identification of neuronal and astrocyte proteins interacting with extracellularly applied oligomeric and fibrillar alpha-synuclein assemblies by mass spectrometry. Data Br 7:221–228. https://doi.org/10.1016/j.dib.2016.02.018

144. Song J-J, Oh S-M, Kwon O-C, Wulansari N, Lee H-S, Chang M-Y et al (2017) Cografting astrocytes improves cell therapeutic outcomes in a Parkinson's disease model. J Clin Investig 128:463–482. https://doi.org/10.1172/JCI93924

145. Song YJC, Halliday GM, Holton JL, Lashley T, O'Sullivan SS, McCann H (2009) Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol 68:1073–1083. https://doi.org/10.1097/NEN.0b013e3181b66f1b

146. Sorrentino ZA, Brooks MMT, Hudson V, Rutherford NJ, Golde TE, Giasson BI et al (2017) Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity. Mol Neurodegener 12:40. https://doi.org/10.1186/s13024-017-0182-z

147. Sorrentino ZA, Vijayaraghavan N, Gorion K-M, Riffe CJ, Strang KH, Caldwell J et al (2018) Physiological carboxy-truncation of α-synuclein potentiates the prion-like formation of pathological inclusions. J Biol Chem. https://doi.org/10.1074/jbc.ra118.005603

148. Sorrentino ZA, Xia Y, Funk C, Riffe CJ, Rutherford NJ, Ceballos Diaz C et al (2018) Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration. Neurobiol Dis 120:98–106. https://doi.org/10.1016/j.nbd.2018.09.005

149. Stefanova N, Klimaschewski L, Poewe W, Wenning GK, Reindl M (2001) Glial cell death induced by overexpression of alpha-synuclein. J Neurosci Res 65:432–438. https://doi.org/10.1002/jnr.1171

150. Sullivan A, O'Keeffe G (2016) Neurotrophic factor therapy for Parkinson's disease: past, present and future. Neural Regen Res 11:205. https://doi.org/10.4103/1673-5374.177710

151. Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J et al (2017) T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature 546:656–661. https://doi.org/10.1038/nature22815

152. Sung JY, Park SM, Lee C-H, Um JW, Lee HJ, Kim J et al (2005) Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J Biol Chem 280:25216–25224. https://doi.org/10.1074/jbc.M503341200

153. Surendranathan A, Su L, Mak E, Passamonti L, Hong YT, Arnold R et al (2018) Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain 141:3415–3427. https://doi.org/10.1093/brain/awy265

154. Surmeier DJ, Obeso JA, Halliday GM (2017) Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 18:101–113. https://doi.org/10.1038/nrn.2016.178

155. Taipa R, Pereira C, Reis I, Alonso I, Bastos-Lima A, Melo-Pires M et al (2016) DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology. Brain 139:1680–1687. https://doi.org/10.1093/brain/aww080

156. Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Masliah E (2000) C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol 99:296–304

157. Takeda H, Inazu M, Matsumiya T (2002) Astroglial dopamine transport is mediated by norepinephrine transporter. Naunyn Schmiedebergs Arch Pharmacol 366:620–623. https://doi.org/10.1007/s00210-002-0640-0

158. Tanji K, Imaizumi T, Yoshida H, Mori F, Yoshimoto M, Satoh K et al (2001) Expression of alpha-synuclein in a human glioma cell line and its up-regulation by interleukin-1beta. NeuroReport 12:1909–1912

159. Terada S, Ishizu H, Haraguchi T, Takehisa Y, Tanabe Y, Kawai K et al (2000) Tau-negative astrocytic star-like inclusions and coiled bodies in dementia with Lewy bodies. Acta Neuropathol 100:464–468

160. Terada S, Ishizu H, Yokota O, Tsuchiya K, Nakashima H, Ishihara T et al (2003) Glial involvement in diffuse Lewy body disease. Acta Neuropathol 105:163–169. https://doi.org/10.1007/s00401-002-0622-9

161. Theillet F-X, Binolfi A, Bekei B, Martorana A, Rose HM, Stuiver M et al (2016) Structural disorder of monomeric α-synuclein persists in mammalian cells. Nature 530:45–50. https://doi.org/10.1038/nature16531

162. Togo T, Iseki E, Marui W, Akiyama H, Uéda K, Kosaka K (2001) Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. J Neurol Sci 184:71–75

163. Tong J, Ang L-C, Williams B, Furukawa Y, Fitzmaurice P, Guttman M et al (2015) Low levels of astroglial markers in Parkinson's disease: relationship to alpha-synuclein accumulation. Neurobiol Dis 82:243–253. https://doi.org/10.1016/j.nbd.2015.06.010

164. Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M et al (2010) Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain 133:172–188. https://doi.org/10.1093/brain/awp282

165. Uchihara T, Giasson BI (2016) Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol 131:49–73. https://doi.org/10.1007/s00401-015-1485-1

166. Vasile F, Dossi E, Rouach N (2017) Human astrocytes: structure and functions in the healthy brain. Brain Struct Funct. https://doi.org/10.1007/s00429-017-1383-5

167. Victoria GS, Zurzolo C (2017) The spread of prion-like proteins by lysosomes and tunneling nanotubes: implications for neurodegenerative diseases. J Cell Biol 216:2633–2644. https://doi.org/10.1083/jcb.201701047

168. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H (2000) NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol 99:14–20

169. Wakabayashi K, Takahashi H (1996) Gallyas-positive, tau-negative glial inclusions in Parkinson's disease midbrain. Neurosci Lett 217:133–136

170. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F (1988) Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 76:217–221

171. Williamson TP, Johnson DA, Johnson JA (2012) Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity. Neurotoxicology 33:272–279. https://doi.org/10.1016/j.neuro.2012.01.015

172. Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ (2003) Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science 302:1769–1772. https://doi.org/10.1126/science.1090389

173. Winner BM, Zhang H, Farthing MM, Karchalla LM, Lookingland KJ, Goudreau JL (2017) Metabolism of dopamine in nucleus accumbens astrocytes is preserved in aged mice exposed to MPTP. Front Aging Neurosci 9:410. https://doi.org/10.3389/fnagi.2017.00410

174. Woodard CM, Campos BA, Kuo S-H, Nirenberg MJ, Nestor MW, Zimmer M et al (2014) iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease. Cell Rep 9:1173–1182. https://doi.org/10.1016/j.celrep.2014.10.023

175. Yang YX, Latchman DS (2008) Nurr1 transcriptionally regulates the expression of α-synuclein. NeuroReport 19:867–871. https://doi.org/10.1097/WNR.0b013e3282ffda48

176. Yeh T-H, Lee DY, Gianino SM, Gutmann DH (2009) Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. Glia 57:1239–1249. https://doi.org/10.1002/glia.20845

177. Yokota O, Terada S, Ishizu H, Tsuchiya K, Kitamura Y, Ikeda K et al (2002) NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC). Acta Neuropathol 104:333–341. https://doi.org/10.1007/s00401-002-0545-5

178. Yun SP, Kam T-I, Panicker N, Kim S, Oh Y, Park J-S et al (2018) Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nat Med 24:931–938. https://doi.org/10.1038/s41591-018-0051-5

179. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML et al (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19:533–542. https://doi.org/10.1096/fj.04-2751com

180. Zhang Z, Shen Y, Luo H, Zhang F, Peng D, Jing L et al (2018) MANF protects dopamine neurons and locomotion defects from a human α-synuclein induced Parkinson's disease model in *C. elegans* by regulating ER stress and autophagy pathways. Exp Neurol 308:59–71. https://doi.org/10.1016/j.expneurol.2018.06.016

181. Zhou W, Bercury K, Cummiskey J, Luong N, Lebin J, Freed CR (2011) Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J Biol Chem 286:14941–14951. https://doi.org/10.1074/jbc.M110.211029

182. Zhu D, Tan KS, Zhang X, Sun AY, Sun GY, Lee JC-M (2005) Hydrogen peroxide alters membrane and cytoskeleton properties and increases intercellular connections in astrocytes. J Cell Sci 118:3695–3703. https://doi.org/10.1242/jcs.02507

183. Zondler L, Miller-Fleming L, Repici M, Gonçalves S, Tenreiro S, Rosado-Ramos R et al (2014) DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease. Cell Death Dis 5:e1350. https://doi.org/10.1038/cddis.2014.307